CytomX Therapeutics (CTMX) Q4 2024 Annual Earnings
CTMX·Reported March 6, 2025·After market close
CytomX Therapeutics reported Q4 2024 revenue of $38.1M, beat analyst consensus of $13.0M by $25.1M. Diluted EPS came in at $0.22, beat the $-0.23 consensus by $0.45.
Revenue
$38.1Mbeat by $25.1M
Consensus: $13.0MDiluted EPS
$0.22beat by $0.45
Consensus: $-0.23
Financial Snapshot
Trailing eight quarters through Q4 2024
Q4 2024 Earnings FAQ
Common questions about CytomX Therapeutics's Q4 2024 earnings report.
CytomX Therapeutics (CTMX) reported Q4 2024 earnings on March 6, 2025 after market close.
CytomX Therapeutics reported revenue of $38.1M and diluted EPS of $0.22 for Q4 2024.
Revenue beat the consensus estimate of $13.0M by $25.1M. EPS beat the consensus estimate of $-0.23 by $0.45.
You can read the 10-K periodic report (0000950170-25-034575) directly on SEC EDGAR. The filing index links above go to sec.gov.